Citigroup Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its target price reduced by research analysts at Citigroup from $9.00 to $6.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the health services provider’s stock. Citigroup’s price objective would indicate a potential upside of 16.73% from the stock’s current price.

TDOC has been the subject of several other research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a research report on Thursday, February 26th. Bank of America upgraded Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price for the company in a report on Thursday, February 26th. Wells Fargo & Company cut their price target on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, February 26th. Stifel Nicolaus decreased their price objective on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Finally, Barclays began coverage on Teladoc Health in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.56.

Teladoc Health Stock Up 0.8%

Shares of NYSE:TDOC opened at $5.14 on Tuesday. The business’s 50 day moving average is $5.86 and its 200 day moving average is $7.16. The stock has a market cap of $916.98 million, a P/E ratio of -4.51 and a beta of 2.13. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.90. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The firm had revenue of $642.27 million during the quarter, compared to the consensus estimate of $635.33 million. During the same period in the previous year, the company posted ($0.28) earnings per share. The firm’s quarterly revenue was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Sell-side analysts predict that Teladoc Health will post -1.16 EPS for the current year.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds and other institutional investors have recently modified their holdings of TDOC. PNC Financial Services Group Inc. grew its position in Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares during the last quarter. Aster Capital Management DIFC Ltd increased its position in shares of Teladoc Health by 101.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after acquiring an additional 2,425 shares during the period. International Assets Investment Management LLC purchased a new position in Teladoc Health in the 4th quarter worth $45,000. Finally, Bayforest Capital Ltd acquired a new stake in Teladoc Health during the 3rd quarter worth about $58,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Oppenheimer cut its price target but retained an “outperform” rating, now $7 (from $12). The continued outperform stance and remaining upside (~36% from current levels) can be viewed as supportive for the stock. Teladoc Health price target lowered by Oppenheimer
• Positive Sentiment: Management will present at the Barclays 28th Annual Global Healthcare Conference on March 10. Investor access to CEO remarks and Q&A could clarify 2026 guidance and strategy, which is typically positive for sentiment if management provides reassuring detail. Teladoc to Participate in Investor Conference
• Neutral Sentiment: Teladoc filed an inducement award for a new Chief Growth Officer — 57,034 RSUs plus performance stock units. This is a standard hiring incentive (some dilution risk) but not likely material to valuation absent other changes. Teladoc Employee Inducement Award
• Neutral Sentiment: Aggregated analyst coverage now averages to a “Hold” per a recent synopsis — suggests mixed sentiment among brokers and limited near-term analyst-driven upside until clearer fundamental improvements. Teladoc Receives Average Hold Rating
• Negative Sentiment: Citigroup lowered its price target from $9 to $6 and moved to a “neutral” rating — a downgrade in target that reduces analyst-implied upside and can pressure sentiment. Citigroup Lowers Price Target
• Negative Sentiment: A report flagged a Russell 1000 rebalancing/target cut impacting Teladoc, which can trigger index-related selling or reduced passive demand and weigh on near-term price action. Russell 1000 Drops on Target Cut

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.